CSPC Pharmaceutical Group Limited

SEHK:1093 Voorraadrapport

Marktkapitalisatie: HK$59.3b

CSPC Pharmaceutical Group Inkomsten in het verleden

Verleden criteriumcontroles 2/6

CSPC Pharmaceutical Group is de winst gegroeid met een gemiddeld jaarlijks percentage van 8%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 5.7%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 8% per jaar. Het rendement op eigen vermogen van CSPC Pharmaceutical Group is 14.3%, en het heeft een nettomarge van 17%.

Belangrijke informatie

8.0%

Groei van de winst

8.2%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie5.6%
Inkomstengroei8.0%
Rendement op eigen vermogen14.3%
Nettomarge17.0%
Laatste winstupdate30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Is CSPC Pharmaceutical Group Limited (HKG:1093) Trading At A 48% Discount?

Nov 15
Is CSPC Pharmaceutical Group Limited (HKG:1093) Trading At A 48% Discount?

Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

Oct 16
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%

Sep 30
Earnings Not Telling The Story For CSPC Pharmaceutical Group Limited (HKG:1093) After Shares Rise 26%

CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected

Aug 08
CSPC Pharmaceutical Group Limited (HKG:1093) Investors Are Less Pessimistic Than Expected

Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

Jun 17
Here's Why CSPC Pharmaceutical Group (HKG:1093) Can Manage Its Debt Responsibly

CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

May 29
CSPC Pharmaceutical Group Limited Just Recorded A 20% Revenue Beat: Here's What Analysts Think

CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14

May 21
CSPC Pharmaceutical Group (HKG:1093) Has Announced A Dividend Of CN¥0.14

CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14

Apr 29
CSPC Pharmaceutical Group (HKG:1093) Will Pay A Dividend Of CN¥0.14

There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price

Apr 22
There's Reason For Concern Over CSPC Pharmaceutical Group Limited's (HKG:1093) Price

CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14

Apr 01
CSPC Pharmaceutical Group's (HKG:1093) Dividend Will Be CN¥0.14

CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate

Jan 22
CSPC Pharmaceutical Group Limited (HKG:1093) Shares Could Be 49% Below Their Intrinsic Value Estimate

Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

Jan 04
Some Confidence Is Lacking In CSPC Pharmaceutical Group Limited's (HKG:1093) P/E

Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?

Oct 22
Are Investors Undervaluing CSPC Pharmaceutical Group Limited (HKG:1093) By 36%?

Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?

Sep 21
Is CSPC Pharmaceutical Group (HKG:1093) A Risky Investment?

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price

Jul 09
CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 62% Above Its Share Price

Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?

Jun 20
Does CSPC Pharmaceutical Group (HKG:1093) Have A Healthy Balance Sheet?

CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year

Jun 01
CSPC Pharmaceutical Group's (HKG:1093) Shareholders Will Receive A Bigger Dividend Than Last Year

CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11

Apr 04
CSPC Pharmaceutical Group (HKG:1093) Is Increasing Its Dividend To CN¥0.11

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price

Mar 12
CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 92% Above Its Share Price

Opbrengsten en kosten

Hoe CSPC Pharmaceutical Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

SEHK:1093 Opbrengsten, kosten en inkomsten (CNY Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Sep 2430,2715,1579,9485,032
30 Jun 2431,6545,92710,3035,069
31 Mar 2432,3806,05710,8724,992
31 Dec 2331,4505,87310,3304,830
30 Sep 2331,3066,11810,4104,744
30 Jun 2331,4076,09210,9734,406
31 Mar 2331,1166,11611,1774,093
31 Dec 2230,9376,09111,5103,987
30 Sep 2230,7215,73811,9153,845
30 Jun 2229,6555,50911,6113,704
31 Mar 2229,0075,53811,7003,643
31 Dec 2127,8675,60511,4533,433
30 Sep 2126,3695,97710,7473,132
30 Jun 2126,1755,90810,7033,050
31 Mar 2125,5515,47210,3323,013
31 Dec 2024,9425,16010,3232,890
30 Sep 2024,5584,42110,5222,765
30 Jun 2023,5154,15010,2872,511
31 Mar 2022,7353,92210,0502,108
31 Dec 1922,1033,7149,4612,000
30 Sep 1921,3353,6258,8871,928
30 Jun 1920,1353,4548,2021,725
31 Mar 1918,8353,2947,4261,543
31 Dec 1817,7173,0816,8411,342
30 Sep 1816,8772,9056,3371,346
30 Jun 1815,7292,7345,664973
31 Mar 1813,9592,4434,839912
31 Dec 1712,8772,3074,178679
30 Sep 1712,2032,1953,747277
30 Jun 1711,6592,0683,410282
31 Mar 1711,3831,9793,2030
31 Dec 1611,0751,8812,9920
30 Sep 1610,4391,7112,7250
30 Jun 1610,1181,6072,5760
31 Mar 169,6561,4732,4190
31 Dec 159,5451,3952,3470
30 Sep 159,2841,3052,2020
30 Jun 159,0721,1922,0450
31 Mar 158,9191,1261,9380
31 Dec 148,7621,0151,8710
30 Sep 148,4238961,7480
30 Jun 148,1978491,6860
31 Mar 148,0018141,6270
31 Dec 137,7687601,5000

Kwaliteitswinsten: 1093 heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (17%) 1093 } zijn lager dan vorig jaar (19.5%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: De winst van 1093 is de afgelopen 5 jaar met 8% per jaar gegroeid.

Versnelling van de groei: De winstgroei 1093 is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.

Winst versus industrie: 1093 had het afgelopen jaar een negatieve winstgroei ( -15.7% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Pharmaceuticals ( 9.4% ).


Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 14.3% ) van 1093 wordt als laag beschouwd.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden